| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2014: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2012: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
We have been conducting International Collaborative TB Research in Asia. Anti-TB drug-induced liver injury (AT-DILI) is a main reason of treatment failure. A total of 138 Thai TB patients including 53 AT-DILI cases and 366 Japanese TB patients including 73 AT-DILI cases were enrolled. The odds ratios of N-acetyltransferase 2 (NAT2) slow acetylator (SA) status with AT-DILI were 8.80 (95% confidence interval (CI) 4.01-19.31, P-value = 1.53*10-8) in Thais and 4.32 (95%CI 1.93-9.66, p=5.56*10-5) in Japanese. Our results demonstrated that the acetylator status of NAT2 is an important determinant for AT-DILI in Asia. We performed first-phase genome-wide association study to search for the additional genetic factors. International meta-analysis and cost-effectiveness analysis may provide data to support the individualization of anti-TB treatment in Asian TB patients based on genotyping of the NAT2 and additional genes.
|
